Search the Newsreel

H.C. Wainwright cuts Shattuck Labs stock price target on trial expansion

H.C. Wainwright has lowered its price target for Shattuck Labs (NASDAQ:STTK) to $14 from $18, while maintaining a Buy rating, following the company's Q2 2026 financial results and an expanded Phase 2b trial for its lead asset, SL-325. Despite the price target cut, the …

Needham Maintains Shattuck Labs(STTK.US) With Buy Rating, Maintains Target Price $17

Needham has reiterated its Buy rating for Shattuck Labs (STTK.US) and maintained its price target at $17. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.

Several Insiders Invested In Shattuck Labs Flagging Positive News

Several insiders at Shattuck Labs (NASDAQ:STTK) have recently bought shares, with one independent director purchasing US$250k worth. While this buying activity occurred at a price below current market value, it suggests insiders view the company's prospects positively. Despite a recent loss, the substantial insider …

Form 8K Shattuck Labs Inc For: 11 August By Investing.com

This article announces that Shattuck Labs Inc. filed a Form 8K on August 11, according to Investing.com. The brief news item includes the company's stock symbol STTK and its positive performance for the day. No further details about the content of the Form 8K …

Is Shattuck Labs Inc (STTK) Overvalued Following Q2 Earnings Mis

Shattuck Labs, Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 108% Upside

Analysts have lowered the average 12-month price target for Shattuck Labs, Inc. (STTK) stock from $15 to $14.86, implying a potential upside of 108% based on the August 10 closing price. Despite the reduction, the consensus rating from 9 covering analysts remains a "Buy," …

STTK Maintained by HC Wainwright & Co. -- Price Target Lowered to $14

HC Wainwright & Co. has maintained a 'Buy' rating for Shattuck Labs (STTK) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook due to the company's significant overvaluation, low profitability, and mixed insider sentiment. Despite developing innovative therapies, the stock …

HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00

HC Wainwright has reduced its price target for Shattuck Labs (NASDAQ:STTK) to $14.00 from $18.00, while maintaining a "buy" rating, indicating a potential upside of approximately 94%. Despite the lowered target, analysts collectively give the company a "Moderate Buy" rating with an average target …

Shattuck Labs 2Q Loss/Shr 12c >STTK

Shattuck Labs (STTK) reported a second-quarter loss per share of 12 cents. Further details regarding their financial performance were not provided in this brief announcement.

Shattuck Labs (NASDAQ:STTK) Releases Earnings Results, Hits Expectations

Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases

Shattuck Labs has released an investor deck detailing its strategy to develop DR3-blocking antibodies, primarily SL-325, for inflammatory and immune-mediated diseases. A Phase 2b trial for SL-325 in Crohn's disease is set to begin in Q3 2026, with initial data expected in 1H 2028. …

Shattuck Labs Reports $15.2 Million Q2 Loss and 2029 Cash Runway

Shattuck Labs (STTK) reported a Q2 2026 net loss of $15.2 million, with $0 revenue, and expects its $208.3 million in cash to fund operations into 2029. The company provided updates on its SL-325 clinical trial, with Phase 2b starting in Q3 2026, and …

Shattuck Labs GAAP EPS of -$0.12 in-line

* Shattuck Labs press release [https://seekingalpha.com/pr/20614116-shattuck-labs-reports-second-quarter-2026-financial-results-and-recent-business-highlights] (STTK [https://seekingalpha.com/symbol/STTK]): Q2 GAAP EPS of -$0.12 in-line. * As of June 30, 2026, cash and cash equivalents, and short-term investments, were approximately $208.3 million. Shattuck’s current cash and cash equivalents, and short-term investments are expected to fund …

Shattuck Labs Releases Q2 2026 10-Q Filing Highlighting Key Risk Factors and Share Count

Shattuck Labs, Inc. has filed its Form 10-Q for the second quarter of 2026 with the SEC, making the report available on August 11, 2026. This filing highlights key risk factors and provides an update on the company's share count. Readers can access the …

Shattuck Labs Inc (STTK) Earnings Forecast: Future EPS & Revenue Growth Estimates

Shattuck Labs, Inc. $STTK Stock Holdings Lifted by Renaissance Technologies LLC

Renaissance Technologies LLC significantly increased its stake in Shattuck Labs (NASDAQ:STTK) by 77.4% in Q1 2026, bringing its total holdings to 604,500 shares. Institutional investors and hedge funds collectively own 58.74% of the company's stock, while corporate insiders have recently sold shares totaling $591,850. …

Certain Common Stock of Shattuck Labs, Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2026.

Shattuck Labs, Inc. announced that certain common stocks are under a lock-up agreement ending on August 9, 2026. This lock-up period, starting from June 9, 2026, restricts directors and executive officers from selling these shares for 60 days without underwriter consent. The company, focused …

Shattuck Labs Inc (STTK) Stock News Today

This article provides current stock information for Shattuck Labs Inc (STTK), including its stock price, market cap, and a note that more news is coming soon. As of the close on August 7th, STTK was trading at $7.270, up 1.54%.

Shattuck Labs (STTK) Projected to Release Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is projected to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts anticipating a loss of $0.1241 per share. The company's stock has seen substantial growth from its one-year low, and institutional investors hold a significant …

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $12.63, significantly above its current share price of $7.37. Recent analyst updates from Needham, Wedbush, and Leerink Partners have been positive, raising price targets …

Shattuck Labs Inc (STTK) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Shattuck Labs Inc (STTK), detailing its current price momentum, support and resistance levels, and indicator and moving average readings. It notes that the stock is currently trading between a resistance of $7.89 and a support of $6.15, …

Shattuck Labs Inc (STTK) Institutional Confidence

Shattuck Labs Inc (STTK) has an institutional shareholding score of 5.00, placing it 132nd out of 384 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 65.78%, showing a 15.86% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding …

Shattuck Labs, Inc. Revenue Breakdown – NASDAQ:STTK

This article provides a revenue breakdown for Shattuck Labs, Inc. (NASDAQ: STTK). In the last fiscal year, the company generated $1.00 million USD, with its "First-in-class Antibody" segment contributing the entirety of this amount. The United States was the sole geographic contributor to this …

This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Benzinga reports on three new analyst initiations. HSBC initiated coverage on Space Exploration Technologies Corp (NASDAQ: SPCX) with a Hold rating and a $115 price target. Mizuho initiated SunocoCorp (NYSE: SUNC) with an Outperform rating and an $83 price target. JP Morgan began coverage …

Shattuck Labs Inc (STTK) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Shattuck Labs Inc (STTK), noting its current valuation score is 7.06, ranking 254 out of 385 in its industry. The company's P/E ratio stands at -12.09, which is significantly below its recent high. The article indicates that …

STTK|Shattuck Labs Inc|Price:6.745|Chg%:-0.075

This article provides an in-depth analysis of Shattuck Labs Inc (STTK) stock, highlighting its market trends, real-time quotes, and related analysis. It covers key financial figures, insights into its healthy fundamentals and high growth potential, and an overall Buy rating from analysts with a …

STTK|Shattuck Labs Inc|Price:7.430|

Shattuck Labs Inc. (STTK) is a biotechnology company focused on developing treatments for inflammatory and immune-mediated diseases. The company's lead product candidate, SL-325, is a monoclonal antibody in Phase I clinical trials, with a half-life extended version, SL-425, also in development. As of Q1 …

Shattuck Labs Inc (STTK) Balance Sheet

This article provides a detailed quarterly and annual balance sheet for Shattuck Labs Inc (STTK), allowing users to evaluate the company's financial health, liquidity, leverage, and return on equity. It presents key financial metrics such as cash, total assets, liabilities, and shareholders' equity over …

TradingKey

This article provides a detailed cash flow statement for Shattuck Labs Inc (STTK) across multiple quarters, broken down into operating, investing, and financing activities. It presents quarterly data with percentage changes year-over-year for various cash flow components. The article also includes a FAQ section …

Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday

Shattuck Labs (STTK) stock rose nearly 5% due to a new "overweight" rating and $10 price target from J.P. Morgan analyst Brian Cheng. Cheng's optimistic view is based on Shattuck's lead drug candidate, SL-325, for inflammatory bowel disease, which showed a clean safety profile …

JPMorgan reiterates Shattuck Labs stock rating on DR3 program

JPMorgan has reiterated its Overweight rating and $10.00 price target for Shattuck Labs (NASDAQ:STTK), citing the potential of its anti-DR3 antibody program, SL-325, for inflammatory and immunological diseases. Despite a significant stock surge, InvestingPro analysis suggests the shares may be overvalued. The company recently …

STTK Initiated Coverage by JP Morgan -- Rating Set at Overweight

JP Morgan has initiated coverage on Shattuck Labs (STTK) with an Overweight rating and a price target of $10.00, indicating potential upside. Despite this positive analyst outlook, GuruFocus assesses STTK as significantly overvalued with a GF Value™ of $1.05 compared to its current price …

JPMorgan Initiates Shattuck Labs at Overweight With $10 Price Target

JPMorgan has initiated coverage of Shattuck Labs (STTK) with an Overweight rating and set a price target of $10.00. This news comes as Shattuck Labs, a biotechnology company focused on inflammatory and immune-mediated diseases, has recently been added to several Russell indices. The company …